On September 5, CanSino opened 11.5% higher, closing up 9.82%; H-share CanSino Biologics opened nearly 9% higher, closing up 7%.
news, CanSino announced that the recombinant novel coronavirus vaccine for inhalation (type 5 adenovirus vector) developed by the company was proposed by the National Health Commission, and the National Medical Products Administration organized the demonstration and agreed to be included in emergency use as a strengthening injection.
At the same time, CanSino said that after the inhaled recombinant novel coronavirus vaccine (type 5 adenovirus vector) is approved for emergency use, if the relevant national departments subsequently purchase and use it, it will have a certain positive impact on the performance of listed companies.
Previously, the recombinant novel coronavirus vaccine developed by CanSino became the first approved adenovirus vector new coronavirus vaccine in China. This time, as the world's first inhaled COVID-19 vaccine approved for emergency use, CanSino has also attracted more attention.
The world's first inhaled new coronavirus vaccine is approved for emergency use
It is understood that the recombinant novel coronavirus vaccine for inhaled (type 5 adenovirus vector) was approved for drug clinical trials in March 2021. The indication is to prevent diseases caused by novel coronavirus infection (COVID-19).
Recombinant novel coronavirus vaccine for inhalation is atomized and inhaled administration method to atomize the vaccine into tiny particles, which enters the respiratory tract and lungs through oral inhalation, which can stimulate the mucosal immune response. This immune method cannot be brought about by intramuscular injection and provides additional protection in the respiratory mucosal tissue. The establishment of mucosa in the respiratory mucosa immunity of makes memory B cells and memory T cells distributed in the respiratory mucosa encounter pathogens earlier than systemic memory cells, so it can inhibit viral replication faster and reduce viral transmission. The 2022 semi-annual report shows that the total investment scale of the recombinant novel coronavirus vaccine for inhalation is expected to be 300 million yuan, with a cumulative investment of 95.502 million yuan.
In this regard, the research report of Guojin Securities (600109) pointed out that the approval of the inhaled dosage form has enriched the commercial layout of CanSino's new crown vaccine . In the future, there is a possibility of further acquisition by Chinese government and entry into the WHO procurement list in the future.
However, this does not mean that CanSino can "live in peace of mind".
According to CanSino's announcement, after inquiry, 9 vaccines in China have been approved by the National Drug Administration for Market Regulation for conditional marketing or emergency use, 3 have been included in the emergency use list of World Health Organization , and many others are in the clinical trial stage.
According to statistics, in addition to the recombinant novel coronavirus vaccine for inhalation by CanSino, eight other domestic new crown vaccines have been approved for marketing or emergency use, namely: China Biologics- Beisheng Institute inactivated vaccine, China Biologics-Wuhan Institute inactivated vaccine, Sinovac inactivated vaccine, CanSino adenovirus vector vaccine, Zhifei Biologics (300122) recombinant protein vaccine, Kangtai Biologics (300601) inactivated vaccine, Institute of Biology of the Medical Academy, and Lizhu Group (000513) recombinant novel coronavirus fusion protein vaccine.
CanSino also reminded of relevant risks in the announcement, saying that even if the product is included in emergency use, its future market sales will still face a fierce competition, and will also be affected by various factors such as the development and changes of the epidemic at home and abroad, the domestic COVID-19 vaccination rate and other factors.
At the same time, CanSino said that before the vaccine is launched, it is necessary to apply for clinical trials, conduct clinical trials, apply for production documents, and issue products batches. The subsequent research and development and administrative approval of the recombinant novel coronavirus vaccine (type 5 adenovirus vector) for inhalation are still uncertain. The company will continue to promote project progress in accordance with relevant national departments and fulfill information disclosure obligations in accordance with relevant regulations.
inhaled new crown vaccine can lead CanSino to fly "performance + stock price" together?
CanSino is engaged in the research and development, production and commercialization of high-quality human vaccines. In March 2019, CanSino Biologics was listed on the H-shares of the main board of the Hong Kong Stock Exchange; on August 13, 2020, CanSino Biologics officially landed on Science and Technology Innovation Board , becoming the first "A+H" vaccine stock since the Science and Technology Innovation Board was launched.In terms of commercialization, on February 25, 2021, the recombinant novel coronavirus vaccine (type 5 adenovirus vector) kewisa , developed by CanSino and the Academy of Military Science, was approved by the State Food and Drug Administration for conditional marketing, becoming the first approved adenovirus vector new coronavirus vaccine in China. As of early June 2022, Kewisa has obtained approval from 11 countries including my country; in June 2021, the bivalent meningococcal vaccine Mui Ne was approved for new drug application approval by the State Food and Drug Administration; in June 2022, the tetravalent meningococcal vaccine Man Haixin was officially sold domestically.
In terms of product development, in addition to inhaling recombinant novel coronavirus vaccine, CanSino has many "trump cards" in its hands. The semi-annual report shows that the leading domestic new coronavirus mRNA vaccine has conducted phase II clinical trials; the leading domestic DTcP and DTcP enhancement vaccine for infants and young children has completed phase I clinical trials; the innovative global PBPV pneumonia protein vaccine has completed phase Ia clinical trials; the innovative global TB-tuberculosis enhancement vaccine has also completed phase Ib clinical trials; the leading domestic PCV13i thirteen-valent pneumonia binding vaccine has conducted phase III clinical trials.
Image source: AVIC Securities Research Institute
Among the products that have been launched, the listing of the recombinant novel coronavirus vaccine (type 5 adenovirus vector) Kevisa has successfully reversed the situation of CanSino's losses for many years. In 2021, CanSino achieved revenue of 4.3 billion yuan and net profit of about 1.914 billion yuan, turning losses into profits year-on-year.
However, this rapid growth trend has not lasted for a long time. In the first half of 2022, due to the high base of the same period last year and the slowdown in the global COVID-19 vaccination rate, resulting in a decrease in vaccine demand and product price adjustments, CanSino's performance declined sharply. In the first half of the year, revenue fell by 69.45% year-on-year to 630 million yuan, and net profit was 12.238 million yuan, a year-on-year decrease of 98.69%.
Just last week, with the release of CanSino's interim results, the stock price once fell to 124.8 yuan per share, setting a record low. In the past year, CanSino's stock price has fallen by 62%.
You should know that in 2020, the issue price of CanSino when it was listed on the Science and Technology Innovation Board was 209.71 yuan per share, second only to Stone Technology , and is also the second highest-issuance price in A-share in history. Now, with the inhaled recombinant novel coronavirus vaccine approved for emergency use, CanSino's stock price has fallen today. In the long run, can the inhaled recombinant novel coronavirus vaccine lead CanSino back to its peak?
China Overseas Securities once stated in its research report that the new crown vaccine has provided CanSino with relatively clear performance support and financial guarantees in the short term, catalyzing the company's rapid growth. At the same time, as the uncertainty of the repeated outbreak of the epidemic is still very large, the protection of the third dose of vaccine has declined over time, and the demand for the fourth dose of vaccine in countries around the world is relatively certain, and the expectation of demand for COVID-19 vaccines has improved significantly compared with the previous ones, and the trend of increasing COVID-19 vaccines may continue in the short term. In addition, CanSino MCV2 and MCV4 products are gradually launched and increased in volume. As my country's first meningococcal quadrivalent combination vaccine product, MCV4 has a relatively obvious first-mover advantage in market competition. It may continue to provide performance growth for CanSino in the future, and CanSino's future growth space may continue to be opened.
More reports about this article have been published on [Hexun Finance APP]. Search for "Hexun Finance" in the app store, download and participate in the index guessing activity to win JD card and 10,000 yuan in cash prize
